A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. [electronic resource]
Producer: 20090716Description: 1069-75 p. digitalISSN:- 1078-0432
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Combined Modality Therapy
- Drug Administration Schedule
- Ethylenediamines -- administration & dosage
- Humans
- Maximum Tolerated Dose
- Multiple Myeloma -- therapy
- Organophosphonates -- administration & dosage
- Platelet Count
- Pyrazines -- administration & dosage
- Radioisotopes -- administration & dosage
- Recurrence
- Samarium -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.